Royalty Pharma Announces Dividend Increase
19 Janeiro 2024 - 10:15AM
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of
directors has declared a dividend for the first quarter of 2024 of
$0.21 per Class A share, reflecting a 5% increase in the company’s
quarterly dividend over the previous quarter’s dividend.
The dividend will be paid on March 15, 2024 to shareholders of
record at the close of business on February 16, 2024.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-profits through small and mid-cap biotechnology companies to
leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s
Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie
and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s
Xtandi, GSK’s Trelegy, Novartis’ Promacta, Johnson & Johnson’s
Tremfya, Roche’s Evrysdi, Pfizer’s Nurtec ODT, Gilead’s Trodelvy,
and 12 development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6637ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Royalty Pharma (NASDAQ:RPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024